Use of an implantable drug delivery system for refractory chronic sickle cell pain

Thomas J. Smith, Patrick J. Coyne, Wally R. Smith, John D. Roberts, Virginia Smith

Research output: Contribution to journalArticlepeer-review

Abstract

An increasing number of chronic sickle cell patients are being treated with sustained-release opioids in the same manner as cancer patients. In a randomized clinical trial of patients with refractory cancer pain, implantable intrathecal drug delivery systems (IDDS) improved clinical success compared to comprehensive medical management alone. We implanted IDDS pumps in two sickle cell patients with refractory bone pain. Both patients achieved rapid and sustained relief of pain, with dramatic reduction in the use of as-needed opioids, crises, and admissions. IDDS may offer relief for sickle cell patients with refractory pain. A prospective trial with more participants is planned.

Original languageEnglish (US)
Pages (from-to)153-154
Number of pages2
JournalAmerican journal of hematology
Volume78
Issue number2
DOIs
StatePublished - Feb 2005
Externally publishedYes

Keywords

  • Chronic sickle cell anemia
  • IDDS
  • Implantable devices
  • Intraspinal therapy
  • Intrathecal therapy
  • Opioids
  • Pain

ASJC Scopus subject areas

  • Hematology

Fingerprint

Dive into the research topics of 'Use of an implantable drug delivery system for refractory chronic sickle cell pain'. Together they form a unique fingerprint.

Cite this